title: Phosphodiesterase 2 as a Therapeutic Target for Heart Failure: Is Upregulation an Option?
authors.affiliation: From the Institute for Translational Research in Biomedicine, Kaohsiung Chang Gung Memorial Hospital, Taiwan, Republic of China.
authors.forename: Samuel H H
authors.initials: SH
authors.lastname: Chan
authors.affiliation: From the Institute for Translational Research in Biomedicine, Kaohsiung Chang Gung Memorial Hospital, Taiwan, Republic of China. jchan@adm.cgmh.org.tw.
authors.forename: Julie Y H
authors.initials: JY
authors.lastname: Chan
mesh_terms: D015105:3',5'-Cyclic-AMP Phosphodiesterases; D000242:Cyclic AMP; D006152:Cyclic GMP; D054678:Cyclic Nucleotide Phosphodiesterases, Type 2; D006333:Heart Failure; D006801:Humans; D010727:Phosphoric Diester Hydrolases; D015854:Up-Regulation
chemical_list: D000242:Cyclic AMP; D010727:Phosphoric Diester Hydrolases; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D054678:Cyclic Nucleotide Phosphodiesterases, Type 2; D006152:Cyclic GMP
keywords: Editorials; cGMP-activated cAMP inhibition; heart failure; phosphodiesterase-2; sympathetic stress; ventricular arrhythmia